Kisplyx

• 

Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

By Sharon Kell|2018-06-07T13:41:25+00:007 Jun 2018|Drug treatments|

The results from the renal cell carcinoma (RCC) group of [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

By Sharon Kell|2018-02-19T10:13:31+00:0019 Feb 2018|Drug treatments|

In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]

Read More

Comments Off on Tyrosine kinase inhibitors for kidney cancer: Past, present and future

Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

By Sharon Kell|2018-01-10T14:51:13+00:0010 Jan 2018|Drug treatments|

The US Food and Drug Administration (FDA) have granted Breakthrough [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

Sequencing of treatments for advanced kidney cancer remains uncertain

By Sharon Kell|2018-01-09T14:28:59+00:009 Jan 2018|Drug treatments|

There are now a number of licensed drug options available [...]

Read More

Comments Off on Sequencing of treatments for advanced kidney cancer remains uncertain

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

By Sharon Kell|2017-12-08T09:36:50+00:008 Dec 2017|Drug treatments|

Fantastic news for people with advanced kidney cancer: the lenvatinib [...]

Read More

Comments Off on Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

The evolving management of advanced renal cell carcinoma

By Sharon Kell|2017-12-07T14:20:44+00:007 Dec 2017|Drug treatments|

This article, published in UroToday this week, is a nice summary [...]

Read More

Comments Off on The evolving management of advanced renal cell carcinoma

• 

European Society of Medical Oncology (ESMO) highlights from the IKCC

By Sharon Kell|2017-09-19T13:42:38+00:0019 Sep 2017|Drug treatments|

The International Kidney Cancer Coalition (IKCC) had a booth at [...]

Read More

Comments Off on European Society of Medical Oncology (ESMO) highlights from the IKCC

• 

Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer

By Sharon Kell|2017-09-11T11:14:20+00:0011 Sep 2017|Drug treatments|

Interim results from Study 111, a phase Ib/II clinical trial [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

By Sharon Kell|2016-09-16T19:33:27+00:0016 Sep 2016|Drug treatments|

The European Commission has approved Kisplyx (lenvatinib) for the treatment [...]

Read More

Comments Off on European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer